ALung Technologies Forms Trial Steering Committee

15 November 2016 Press Release, Recent News

Renowned physicians will oversee landmark trial of the Hemolung RAS in patients with COPD. PITTSBURGH (November 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the formation of its Trial Steering Committee (TSC) for its upcoming pivotal trial (read more)

New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

ALung’s artificial lung technology selected for use in landmark respiratory failure trial

2 December 2015 Press Release

The Hemolung Respiratory Assist System will be exclusively utilized in the 1120-patient study. PITTSBURGH  (December 2, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today its participation in the world’s first and largest pivotal trial of ECCO2R technology. The (read more)

ALung Technologies Receives Expedited Access Pathway Designation from FDA for Hemolung Respiratory Assist System

4 November 2015 Press Release

Designation will facilitate introduction of breakthrough respiratory technology in the United States Pittsburgh, PA (November 4, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today that its Hemolung Respiratory Assist System (RAS) has received Expedited Access Pathway (EAP) designation (read more)

New Publications Show Promise of Improved Artificial Lung Devices

3 August 2015 Press Release, Recent News

Technology developed at the University of Pittsburgh and licensed by ALung enhances the performance of artificial lung devices, paving the way for the development of less invasive respiratory support systems. Pittsburgh, PA (August 3, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute (read more)

ALung Receives CE Mark for New Hemolung XG4 Cartridge and Catheter Kits

18 June 2015 Press Release, Recent News

The new Hemolung XG4 Cartridge and Catheter Kits further simplify initiation of Respiratory Dialysis®. Pittsburgh, PA (June 18, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received CE mark approval for its next generation Hemolung (read more)

ALung Appoints David Motley to its Board of Directors

9 April 2015 Press Release

PITTSBURGH, PA (April 9, 2015) – ALung Technologies, the leading provider of low-flow extracorporeal CO2 removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the appointment of David L. Motley to the Company’s Board of Directors. Mr. Motley was elected to the Board at the Company’s annual shareholder meeting held on March 26, (read more)

ALung Launches Next Generation Extracorporeal CO2 Removal System

12 February 2015 Press Release

New Hemolung CR4 Controller provides unparalleled features and simplicity. The Hemolung CR4 Controller, part of the Hemolung Respiratory Assist System, provides extracorporeal carbon dioxide removal (ECCO2R) for patients suffering from acute respiratory failure.  Pittsburgh, PA (February 12, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients (read more)

ALung Receives Marketing Clearance for Hemolung RAS in Australia

14 January 2015 Press Release

Partners with Medtel Australia as Distributor Pittsburgh, PA (January 14, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received marketing clearance from the Australian Therapeutic Goods Administration (TGA) for its Hemolung Respiratory Assist System (RAS). (read more)

ALung Releases its 2014 Year in Review Summary

23 December 2014 Press Release

Pittsburgh, PA (December 23, 2014) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today released its first Year in Review Summary, covering 2014. ALung experienced significant year over year growth in 2014, with utilization of its Hemolung Respiratory Assist System (RAS) (read more)